Chao Lei

Dr. Chao Lei

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YLYanbo Li
Yanbo Li
ZCZhengmin Cao
Zhengmin Cao
YLYan-ping Lu
Yan-ping Lu
CLChao Lei
Chao Lei
WLWenliang LV
Wenliang LV
Recent insights into the immune response in fibrosis have provided valuable perspectives for the treatment of liver fibrosis. Macrophages, as the most abundant immune cells in the liver, are key drivers of liver fibrosis. They are extensively involved in tissue damage, chronic inflammation, and the progression and regression of liver fibrosis. This study aims to conduct a bibliometric analysis and literature review on the mechanisms by which macrophages contribute to liver fibrosis. Specifically, we analyzed a bibliometric dataset comprising 1,312 papers from 59 countries, 1,872 institutions, and 9,784 authors. Keyword co-occurrence analysis identified key research hotspots, including the role of macrophage subtypes in obesity-related metabolic disorders, the crosstalk between macrophages and hepatic stellate cells through mechanoimmunology, emerging strategies for immune modulation targeting macrophages to promote fibrosis regression and liver regeneration, and new discoveries regarding macrophage crosstalk with other immune cells. In conclusion, this study provides a visual analysis of the current research landscape, hotspots, and trends in the field of macrophages and liver fibrosis, and discusses future directions for further exploration in this area.

7 October 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYanbo Li
Yanbo Li
YLYanping Lu
Yanping Lu
BHBohao Huang
Bohao Huang
CLChao Lei
Chao Lei
QWQing juan Wu
Qing juan Wu
JWJiuchong Wang
Jiuchong Wang
The diagnostic and therapeutic potential of neutrophil extracellular traps (NETs) in liver fibrosis (LF) has not been fully explored. We aim to screen and verify NETs-related liver fibrosis biomarkers through machine learning. In order to obtain NETs-related differentially expressed genes (NETs-DEGs), differential analysis and WGCNA analysis were performed on the GEO dataset (GSE84044, GSE49541) and the NETs dataset. Enrichment analysis and protein interaction analysis were used to reveal the candidate genes and potential mechanisms of NETs-related liver fibrosis. Biomarkers were screened using SVM-RFE and Boruta machine learning algorithms, followed by immune infiltration analysis. A multi-stage model of fibrosis in mice was constructed, and neutrophil infiltration, NETs accumulation and NETs-related biomarkers were characterized by immunohistochemistry, immunofluorescence, flow cytometry and qPCR. Finally, the molecular regulatory network and potential drugs of biomarkers were predicted. A total of 166 NETs-DEGs were identified. Through enrichment analysis, these genes were mainly enriched in chemokine signaling pathway and cytokine-cytokine receptor interaction pathway. Machine learning screened CCL2 as a NETs-related liver fibrosis biomarker, involved in ribosome-related processes, cell cycle regulation and allograft rejection pathways. Immune infiltration analysis showed that there were significant differences in 22 immune cell subtypes between fibrotic samples and healthy samples, including neutrophils mainly related to NETs production. The results of in vivo experiments showed that neutrophil infiltration, NETs accumulation and CCL2 level were up-regulated during fibrosis. A total of 5 miRNAs, 2 lncRNAs, 20 function-related genes and 6 potential drugs were identified based on CCL2. This study identified CCL2 as a biomarker for nets-related liver fibrosis, providing a new perspective for understanding the mechanisms of nets-mediated fibrosis and promoting therapeutic discovery.

31 March 2026 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CLChao Lei
Chao Lei
MQMeng Qiao
Meng Qiao
CTChaoren Tan
Chaoren Tan
EGErjun Gao
Erjun Gao
WLWenliang LV
Wenliang LV
ZWZhifei Wang
Zhifei Wang

15 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CLChao Lei
Chao Lei
HZHouyan Zhang
Houyan Zhang
DWDongjie Wu
Dongjie Wu
EGErjun Gao
Erjun Gao
BHBohao Huang
Bohao Huang
WLWenliang LV
Wenliang LV
Hepatocellular carcinoma (HCC) is characterized by marked molecular and histopathological heterogeneity, which limits the performance of conventional clinicopathological risk stratification systems. Hippo-YAP signaling is closely involved in HCC progression and tumor microenvironment regulation. However, how Hippo-YAP pathway activity is reflected in histopathological phenotypes and intercellular communication patterns remains insufficiently understood. We developed a Hippo-YAP pathway activity-guided pathomics framework by integrating H&E whole-slide image features, transcriptomic pathway activity, and survival information from the TCGA-LIHC cohort. Conventional pathomics features and deep learning features were extracted using CellProfiler and ResNet50, respectively. Hippo-YAP pathway activity was quantified by GSVA based on a published 22-gene Hippo-YAP signaling pathway-related gene set. Prognosis-related pathomics features were used to construct an exploratory survival risk model. Single-cell transcriptomic, spatial transcriptomic, immunohistochemical, and CommPath-based cell-cell communication analyses were further performed to characterize the cellular localization, spatial distribution, protein expression, and microenvironmental relevance of NDRG1. A set of pathomics features associated with Hippo-YAP pathway activity and overall survival was identified. A StepCox[forward] + RSF model was selected as an exploratory risk model. However, the model showed substantial performance degradation from the training cohort to the internal validation cohort, with the 3-year AUC decreasing from 0.940 to 0.676 and the C-index decreasing from 0.930 to 0.620. This discrepancy indicates overfitting and limited individual-level discriminative ability. Therefore, the risk score was used only as an internal exploratory stratification variable, and no clinical predictive utility is claimed. Network analysis identified NDRG1 as a candidate molecule linking Hippo-YAP-associated pathomics features with unfavorable prognosis. Multi-level validation independent of risk-score stratification showed that NDRG1 was mainly enriched in malignant tumor cells, relatively concentrated in tumor-core and tumor-edge regions, and showed increased protein expression in HCC tissues. CommPath analysis suggested that NDRG1-positive tumor cells may exhibit enhanced outgoing communication through complement-, metabolism-, extracellular matrix-, and lipid-related signaling programs. Furthermore, NDRG1 protein expression was increased in orthotopic tumor tissues and reduced in lenvatinib-treated tumor tissues. This study presents a Hippo-YAP pathway activity-guided pathomics framework for exploring the relationship among histopathological phenotypes, pathway activity, and tumor microenvironmental communication in HCC. Because of overfitting and weak internal validation performance, the risk model should not be interpreted as a clinically applicable prognostic tool. Instead, the main value of this study lies in identifying NDRG1 as a candidate bridge between Hippo-YAP-associated pathomics features and microenvironmental communication patterns. External validation and functional experiments are required before any clinical or prognostic application can be considered.